| Acute promyelocytic leukemia: evolving therapeutic strategies MS Tallman, C Nabhan, JH Feusner, JM Rowe Blood, The Journal of the American Society of Hematology 99 (3), 759-767, 2002 | 545 | 2002 |
| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 526 | 2014 |
| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis AR Mato, C Nabhan, MC Thompson, N Lamanna, DM Brander, B Hill, ... Haematologica 103 (5), 874, 2018 | 424 | 2018 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 308 | 2020 |
| Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, ... Annals of Oncology 28 (5), 1050-1056, 2017 | 264 | 2017 |
| Chronic lymphocytic leukemia: a clinical review C Nabhan, ST Rosen Jama 312 (21), 2265-2276, 2014 | 225 | 2014 |
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience AR Mato, C Nabhan, PM Barr, CS Ujjani, BT Hill, N Lamanna, ... Blood, The Journal of the American Society of Hematology 128 (18), 2199-2205, 2016 | 216 | 2016 |
| A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era AM Evens, I Helenowski, E Ramsdale, C Nabhan, R Karmali, B Hanson, ... Blood, The Journal of the American Society of Hematology 119 (3), 692-695, 2012 | 181 | 2012 |
| Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer RZ Szmulewitz, CJ Peer, A Ibraheem, E Martinez, MF Kozloff, B Carthon, ... Journal of Clinical Oncology 36 (14), 1389-1395, 2018 | 172 | 2018 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 168 | 2018 |
| Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy JS Abramson, T Feldman, AR Kroll-Desrosiers, LS Muffly, E Winer, ... Annals of oncology 25 (11), 2211-2217, 2014 | 157 | 2014 |
| Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL S Kadri, J Lee, C Fitzpatrick, N Galanina, M Sukhanova, G Venkataraman, ... Blood advances 1 (12), 715-727, 2017 | 134 | 2017 |
| Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in … AK Nooka, C Nabhan, X Zhou, MD Taylor, M Byrtek, TP Miller, ... Annals of oncology 24 (2), 441-448, 2013 | 120 | 2013 |
| MYC‐associated and double‐hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches AM Petrich, C Nabhan, SM Smith Cancer 120 (24), 3884-3895, 2014 | 118 | 2014 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 115 | 2020 |
| Analysis of very elderly (≥ 80 years) non‐hodgkin lymphoma: impact of functional status and co‐morbidities on outcome C Nabhan, SM Smith, I Helenowski, E Ramsdale, B Parsons, R Karmali, ... British journal of haematology 156 (2), 196-204, 2012 | 110 | 2012 |
| Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older C Nabhan, LM Rundhaugen, MB Riley, A Rademaker, L Boehlke, M Jatoi, ... Leukemia research 29 (1), 53-57, 2005 | 94 | 2005 |
| Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia P Strati, JH Uhm, TJ Kaufmann, C Nabhan, SA Parikh, CA Hanson, ... Haematologica 101 (4), 458, 2016 | 91 | 2016 |
| Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma DJ Landsburg, AM Petrich, JS Abramson, AR Sohani, O Press, ... Cancer 122 (4), 559-564, 2016 | 91 | 2016 |
| Gray zone lymphoma with features intermediate between classical H odgkin lymphoma and diffuse large B‐cell lymphoma: C haracteristics, outcomes, and prognostication among a … AM Evens, JA Kanakry, LH Sehn, A Kritharis, T Feldman, A Kroll, ... American journal of hematology 90 (9), 778-783, 2015 | 91 | 2015 |
